On Monday, Genmab stock reached an important technical milestone, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 84, up from 80 the day before.
As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains tend to have an RS Rating of over 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
Is Genmab Stock A Buy?
Genmab stock is building a consolidation with a 47.60 entry. See if the stock can break out in volume at least 40% above average. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
While earnings growth declined in the company's most recently reported quarter from 148% to -24%, the top line grew 88%, up from 50% in the prior report. The next quarterly results are expected on or around May 10.
Genmab stock earns the No. 8 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm and Vertex Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
